Beam Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Current Ratio Growth & History (BEAM)
Beam Therapeutics's current ratio was 13.09 for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 13.09 | 8.26 | +171.35% |
| 2024 | 2024-12-31 | 4.82 | −1.07 | −18.13% |
| 2023 | 2023-12-31 | 5.89 | 1.00 | +20.53% |
| 2022 | 2022-12-31 | 4.89 | −1.08 | −18.05% |
| 2021 | 2021-12-31 | 5.96 | 2.95 | +97.97% |
| 2020 | 2020-12-31 | 3.01 | −0.23 | −7.15% |
| 2019 | 2019-12-31 | 3.24 | — | — |
Beam Therapeutics quarterly current ratio
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 14.57 | 7.82 | +115.86% |
| Q1 2026 | 2026-03-31 | 16.99 | 8.18 | +92.77% |
| Q4 2025 | 2025-12-31 | 13.09 | 8.26 | +171.35% |
| Q3 2025 | 2025-09-30 | 6.02 | 0.33 | +5.80% |
| Q2 2025 | 2025-06-30 | 6.75 | 0.95 | +16.28% |
| Q1 2025 | 2025-03-31 | 8.81 | 2.82 | +47.11% |
| Q4 2024 | 2024-12-31 | 4.82 | −1.07 | −18.13% |
| Q3 2024 | 2024-09-30 | 5.69 | 0.97 | +20.57% |
| Q2 2024 | 2024-06-30 | 5.81 | 0.58 | +11.10% |
| Q1 2024 | 2024-03-31 | 5.99 | 1.07 | +21.66% |
| Q4 2023 | 2023-12-31 | 5.89 | 1.00 | +20.53% |
| Q3 2023 | 2023-09-30 | 4.72 | 0.07 | +1.61% |
| Q2 2023 | 2023-06-30 | 5.22 | −0.33 | −6.00% |
| Q1 2023 | 2023-03-31 | 4.92 | −0.74 | −13.07% |
| Q4 2022 | 2022-12-31 | 4.89 | −1.08 | −18.05% |
| Q3 2022 | 2022-09-30 | 4.64 | −4.64 | −50.00% |
| Q2 2022 | 2022-06-30 | 5.56 | 0.29 | +5.52% |
| Q1 2022 | 2022-03-31 | 5.66 | 0.62 | +12.39% |
| Q4 2021 | 2021-12-31 | 5.96 | 2.95 | +97.97% |
| Q3 2021 | 2021-09-30 | 9.29 | 4.89 | +111.10% |
| Q2 2021 | 2021-06-30 | 5.27 | −0.76 | −12.63% |
| Q1 2021 | 2021-03-31 | 5.04 | −3.22 | −38.96% |
| Q4 2020 | 2020-12-31 | 3.01 | −0.23 | −7.15% |
| Q3 2020 | 2020-09-30 | 4.40 | — | — |
| Q2 2020 | 2020-06-30 | 6.03 | — | — |
| Q1 2020 | 2020-03-31 | 8.26 | — | — |
| Q4 2019 | 2019-12-31 | 3.24 | — | — |
Beam Therapeutics current ratio trends
Over the last five fiscal years, Beam Therapeutics's current ratio increased from 3.01 to 13.09, a change of 10.08. The latest reported quarter, Q2 2026, shows 14.57.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...